InterCure (Canndoc Pharma) is the first and only public company on the Tel Aviv Stock Exchange (TASE: INCR), which holds a valid and permanent license for the entire medical cannabis value chain. The company has recently acquired full ownership and control (100%) of Canndoc Pharma. Canndoc is a leading pioneer in the medical cannabis sector in Israel and worldwide, and has been in engaged in ten years of research, nurturing, cultivating and marketing medical cannabis to thousands of patients with a range of indications that have been approved by Israel’s Ministry of Health and collaborate with partners in Israel and abroad. Visit https://www.canndoc.co.il
In addition, InterCure holds a 17.25% stake in Regenera, a clinical-stage biopharmaceutical company focused on developing a novel drug for neurological disorders. Visit https://www.regenerapharma.com/
InterCure also holds a 9.3% stake in Novellus, a Jerusalem based company, developing a novel technology for precision oncology therapies. Visit www.novellusdx.com.